Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients

Acitretin is widely used to treat psoriasis, but the efficacy varies significantly among individuals. To explore the association between polymorphisms and acitretin efficacy, we enrolled 46 and 105 Chinese Han psoriasis vulgaris patients for discovery and validation phases, respectively. The patients were treated with acitretin (30 mg/day) and calcipotriol ointment for at least 8 weeks, and their genotypes were detected. The wild-type genes and variants were transfected into HEK293 cells, which were then incubated with acitretin. The cellular acitretin concentration was measured by liquid chromatography-mass spectrometry. We found that the polymorphisms rs4149056 in the SLCO1B1 gene and rs2282143 in the SLC22A1 gene were associated with efficacy, both in the discovery (P = 0.013 and P = 0.002) and validation phases (P = 0.028 and P = 0.014), based on a 50% reduction from before to after treatment of the psoriasis area severity index (PASI50). When the PASI75 was used as an efficacy cutoff, a similar conclusion was drawn. The uptake of acitretin was lower with the rs4149056C (P = 0.002) and rs2282143T alleles (P = 0.038) than the wild-type alleles. Our results imply that the rs4149056C and rs2282143T variants decrease the acitretin uptake, and significantly associated with clinical effective responsiveness.

[1]  Weihua Huang,et al.  Validation of a Liquid Chromatography-Electrospray Ionization-Tandem Mass Spectrometry Method for Determination of All-Trans Retinoic Acid in Human Plasma and Its Application to a Bioequivalence Study , 2014, Molecules.

[2]  Jochen Schmitt,et al.  The Psoriasis Area and Severity Index Is the Adequate Criterion to Define Severity in Chronic Plaque-Type Psoriasis , 2005, Dermatology.

[3]  Wei Zhang,et al.  Inhibition of the organic anion-transporting polypeptide 1B1 by quercetin: an in vitro and in vivo assessment. , 2012, British journal of clinical pharmacology.

[4]  I. Song,et al.  Genetic variants of organic cation transporter 1 (OCT1) and OCT2 significantly reduce lamivudine uptake , 2012, Biopharmaceutics & drug disposition.

[5]  J. Polli,et al.  Ondansetron can enhance cisplatin-induced nephrotoxicity via inhibition of multiple toxin and extrusion proteins (MATEs). , 2013, Toxicology and applied pharmacology.

[6]  A. Schinkel,et al.  Deficiency in the Organic Cation Transporters 1 and 2 (Oct1/Oct2 [Slc22a1/Slc22a2]) in Mice Abolishes Renal Secretion of Organic Cations , 2003, Molecular and Cellular Biology.

[7]  S. Feldman,et al.  A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. , 2004, Journal of the American Academy of Dermatology.

[8]  A. Arechalde,et al.  Management of Psoriasis , 2000, BioDrugs.

[9]  A. Ormerod,et al.  British Association of Dermatologists guidelines on the efficacy and use of acitretin in dermatology , 2010, The British journal of dermatology.

[10]  P. Neuvonen,et al.  Cyclosporine markedly raises the plasma concentrations of repaglinide , 2005, Clinical pharmacology and therapeutics.

[11]  P. Neuvonen,et al.  Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake , 2011, Pharmacological Reviews.

[12]  Xiang Chen,et al.  The polymorphisms of growth factor genes (VEGFA & EGF) were associated with response to acitretin in psoriasis. , 2018, Personalized medicine.

[13]  S. Dogra,et al.  Acitretin in psoriasis: an evolving scenario , 2014, International journal of dermatology.

[14]  Jemma C. Hopewell,et al.  Impact of common genetic variation on response to simvastatin therapy among 18 705 participants in the Heart Protection Study , 2012, European heart journal.

[15]  Y. Kanai,et al.  Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. , 2004, Biochemical and biophysical research communications.

[16]  VDR gene polymorphisms are associated with the clinical response to calcipotriol in psoriatic patients. , 2015, Journal of dermatological science.

[17]  V. Patravale,et al.  Psoriasis clinical implications and treatment: a review. , 2013, Critical reviews in therapeutic drug carrier systems.

[18]  HighWire Press,et al.  Drug metabolism and disposition : the biological fate of chemicals. , 1973 .

[19]  Conrad C. Huang,et al.  Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1 , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A review , 2019 .

[21]  Y. Maehara,et al.  Genetic polymorphisms of OCT-1 confer susceptibility to severe progression of primary biliary cirrhosis in Japanese patients , 2014, Journal of Gastroenterology.

[22]  F. Fahrenholz,et al.  Acitretin, an Enhancer of Alpha-Secretase Expression, Crosses the Blood-Brain Barrier and Is Not Eliminated by P-Glycoprotein , 2012, Neurodegenerative Diseases.

[23]  M. Hayden,et al.  Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin , 2011, The Pharmacogenomics Journal.

[24]  William E. Evans,et al.  Pharmacogenomics in the clinic , 2015, Nature.

[25]  Praveen M. Bahadduri,et al.  Rapid Identification of P-glycoprotein Substrates and Inhibitors , 2006, Drug Metabolism and Disposition.

[26]  J. M. Carrascosa,et al.  Acitretina: guía de uso en psoriasis , 2013 .

[27]  Shuang Zhao,et al.  Frizzled-related proteins 4 (SFRP4) rs1802073G allele predicts the elevated serum lipid levels during acitretin treatment in psoriatic patients from Hunan, China , 2018, PeerJ.

[28]  D. Tang-Liu,et al.  Clinical Pharmacokinetics and Drug Metabolism of Tazarotene , 1999, Clinical pharmacokinetics.

[29]  M. Corazza,et al.  Low-dose acitretin in treatment of plaque-type psoriasis: descriptive study of efficacy and safety. , 2015, Acta dermato-venereologica.

[30]  W. Cao,et al.  Acitretin exerted a greater influence on T‐helper (Th)1 and Th17 than on Th2 cells in treatment of psoriasis vulgaris , 2012, The Journal of dermatology.

[31]  Wu Zhu,et al.  Lipidomics profiling reveals the role of glycerophospholipid metabolism in psoriasis , 2017, GigaScience.

[32]  K. Maeda,et al.  Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril , 2006, Clinical pharmacology and therapeutics.

[33]  Martin C. Müller,et al.  The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia. , 2013, Blood.

[34]  S. Feldman,et al.  Low-dose acitretin is associated with fewer adverse events than high-dose acitretin in the treatment of psoriasis. , 2006, Archives of dermatology.

[35]  F. Vanaclocha,et al.  Guidelines for the use of acitretin in psoriasis. Psoriasis Group of the Spanish Academy of Dermatology and Venereology. , 2013, Actas dermo-sifiliograficas.

[36]  M. Pirmohamed,et al.  SLCO1B1 Genetic Variant Associated With Statin-Induced Myopathy: A Proof-of-Concept Study Using the Clinical Practice Research Datalink , 2013, Clinical pharmacology and therapeutics.

[37]  M. Detmar,et al.  Interaction between genetic control of vascular endothelial growth factor production and retinoid responsiveness in psoriasis. , 2006, The Journal of investigative dermatology.

[38]  Min Zhang,et al.  Effects of acitretin on proliferative inhibition and RANTES production of HaCaT cells , 2008, Archives of Dermatological Research.